Vimarsana
Biggest News Aggregation in the World

Page 19 - Keith Kohl News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Keith Kohl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Keith Kohl Today - Breaking & Trending Today

The Golden Age of Shale Is Ancient History - Vimarsana News

The Golden Age of Shale Is Ancient History

Whatever you do, don’t make the mistake of thinking this is the end for oil. In fact, it’s quite the opposite. The shale revolution is far from over...

How to Make Money off Tesla Without Owning a Single Share - Vimarsana News

How to Make Money off Tesla Without Owning a Single Share

Energy and Capital editor Keith Kohl shows investors a new source of lithium that billionaires like Elon Musk are salivating over.

Elon Musk's Biggest Fear Isn't Selling Enough Teslas - Vimarsana News

Elon Musk's Biggest Fear Isn't Selling Enough Teslas

Energy and Capital editor Keith Kohl shows readers why Elon Musk's biggest fear isn't selling enough cars.

One Stock to Rule the EV Revolution - Vimarsana News

One Stock to Rule the EV Revolution

Sometimes an opportunity comes around that is simply too good to ignore. Energy and Capital editor Keith Kohl tells readers about one of the most profitable lessons from the 20th century.

A Story of Investing in Biotech — the One Where Martha Stewart Goes to Jail - Vimarsana News

A Story of Investing in Biotech — the One Where Martha Stewart Goes to Jail

A Story of Investing in Biotech — the One Where Martha Stewart Goes to Jail Posted May 18, 2021 ImClone Systems was a market darling back in the day. The stock price went from single digits to $170 a share in about a year. ImClone was a biotech company that developed a drug called Erbitux.  Today, Erbitux is a cancer medicine that interferes with the spread of cancer cells in the body. The drug is used in combination with other drugs to treat colon and rectal cancer as well as head and neck cancer. It is useful but not a cure-all, and it has competition in the marketplace.